Mathew P, Ahmann G J, Witzig T E, Roche P C, Kyle R A, Greipp P R
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Br J Haematol. 1995 Jun;90(2):459-61. doi: 10.1111/j.1365-2141.1995.tb05175.x.
Prior studies have suggested that loss of plasma cell CD56 expression in multiple myeloma defines a unique patient subset and that CD56 expression reliably discriminates between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). We conducted a study of 68 untreated patients with MM from a single institution to define the clinicopathological correlates of CD56 expression. We find CD56 expression in 55% of MM. Lack of CD56 expression does not define a unique clinicopathological or prognostic entity in MM. Strong CD56 expression can also be found in MGUS and does not help to distinguish from MM.
先前的研究表明，多发性骨髓瘤中浆细胞CD56表达缺失定义了一个独特的患者亚群，并且CD56表达可可靠地区分意义未明的单克隆丙种球蛋白病（MGUS）和多发性骨髓瘤（MM）。我们对来自单一机构的68例未经治疗的MM患者进行了一项研究，以确定CD56表达的临床病理相关性。我们发现55%的MM患者有CD56表达。CD56表达缺失在MM中并未定义一个独特的临床病理或预后实体。在MGUS中也可发现强CD56表达，且无助于与MM相鉴别。
